All In Biotech

Drug Trial Radar · NCT04751539

A Dose-escalation Study of AND017 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AND017 Following Oral Single and Multiple Dose Administration

Last checked: Nov 19, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jul 16, 2018

Primary completion

Feb 11, 2019

Study completion Feb 11, 2019

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.

Conditions

  • Healthy Volunteers

Interventions

  • AND017 single doseDrug

    AND017 administrated as oral single-dose on Day 1 in Part A

  • AND017 multiple doseDrug

    AND017 administrated once daily from Day 1 to Day 10 in Part B

  • PlaceboDrug

    Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluationsTime frame: 17 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.